Pharma Pulse 7/24/24: Addressing OUD Treatment Gaps, Body Dysmorphic Disorder Most Common in Adolescent Girls & more

Addressing OUD Treatment Gaps & Improving Patient Outcomes

In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.

Analysis Determines Body Dysmorphic Disorder Is the Most Common in Adolescent Girls

The findings also demonstrate that body dysmorphic disorder is also associated with high levels of comorbid psychopathology, risk, and psychosocial impairment.

Preparing for the Next Worldwide Tech Outage

CIOs can take steps now to reduce risks associated with today’s IT landscape.

AIDS is Still Not Over, says AHF

As the International AIDS Conference gets underway this week in Munich, Germany, AIDS Healthcare Foundation reminds the world that AIDS is not over amid slowing progress on the pandemic and stubbornly high global mortality.

@fda on Threads

Managing diabetes can be challenging, but there are treatment options that may be available to help. Biosimilars are safe and effective alternatives to reference biologics. Learn more: bit.ly/4c8Q1…

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs